Leland Wilson, Vivus CEO, discusses the optimist outlook for his company after an FDA panel backed its new diet drug, Qnexa; marketing strategies for the new product; and whether his company is now a potential takeover target, with the Fast Money traders.
Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.
There will be no silver bullet to reduce obesity, says Margaret Hamburg, FDA commissioner. Adding that, "generic drugs make a huge difference in patient care."
Generic drugs are in focus at Generic Pharmaceutical Association's annual meeting in Orlando, Florida. The hot button issue: backlog of generic drug applications at the Food & Drug Administration.
What investors should take away from Vivus, as shares soar on FDA nod.
A serious warning is out to patients, doctors and hospitals telling everyone to beware of a fake version of Roche's cancer-fighting drug Avastin. Insight with Scott Gottlieb, MD.
Richard Pops, Alkermes chairman & CEO, discusses the challenges facing the health care industry; FDA approval of a once weekly diabetes drug, and other promising new drug candidates.
The drug developer's stock took a hit Thursday, after data was released linking an ingredient in its weight loss treatment to an increased risk of birth defects.
Dan Bradbury, Amylin CEO, discusses paying Lilly $250M upfront and $1.2B of future sales for the rights to Exenatide, the once weekly version of diabetes drug, Byetta, that's pending FDA approval.
A former Goldman Sachs board member on Wednesday surrendered to federal authorities to face criminal charges stemming from a massive hedge fund insider trading case.
A nationwide listeria outbreak that has killed 25 people who ate tainted cantaloupe was probably caused by unsanitary conditions in the packing shed of the Colorado farm where the melons were grown, federal officials said Wednesday. The New York Times reports.
The federal government has received a surge in complaints in recent months about failed hip replacements, suggesting that serious problems persist with some types of artificial hips even as researchers scramble to evaluate the health dangers. The New York Times reports.
The Obama administration revealed plans Tuesday to cut or roll back hundreds of federal regulations, saying it hoped to save businesses $10 billion and spur job growth.
The Food and Drug Administration is taking on an expanded mission when regulators have little hope for more funding and may even see their budgets cut, the New York Times reports.
People usually think of insider trading as illegally manipulating stock sales for huge profits. But it can also be legal. So just what is insider trading? When can it be legal? Here are the details.
The market has given investors a great opportunity to buy this stock at discount, the "Mad Money" host said.
Swiss drugs industry supplier Lonza is to buy U.S.-listed Arch Chemicals for some $1.2 billion, creating the world's largest player in the microbial control market, the groups said on Monday.
Eli Lilly signaled it could maintain or even boost research spending through 2014, even as company sales and earnings tumble due to expected generic competition for its biggest-selling medicines.
A panel of federal cancer experts says the best-selling cancer drug in the world should no longer be approved to treat breast cancer because it is ineffective and causes dangerous side effects.
The court-appointed receiver who is recovering assets for investors in Allen Stanford's alleged Ponzi scheme is demanding that Libya's sovereign wealth funds return millions of dollars they somehow managed to withdraw just before the firm blew up in 2009, CNBC has learned.